ArticleThe AAPS journal2026
Betting on Biology: Rethinking Probability as the Currency of Risk in Biotechnology Portfolios.
Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uncertainty is an integral facet to the biotechnology and life sciences industry. From early target drug discovery to regulatory approval and commercialization, investment decisions are made under conditions of incomplete knowledge and asymmetric information. Indices of probability, particularly probability of technical and regulatory success, probability of clinical success, and risk-adjusted net present value, have become foundational tools for structuring these uncertainties within portfolio decision-making frameworks. However, their interpretation and application often lack conceptual precision and contextual nuance. This commentary examines the use of probability indices in describing and managing portfolio risk in biotechnology and life sciences. It reflects on their role in assigning risk to new drug targets, novel therapeutic modalities, and stage-specific development programs.
Indexed as
Identifiers
42698049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.